Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 6/20 | 0.46 |
| ▸ | REN | P00797 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668555 | 1.00 | RAB9A (0.65) | RAB9AFKBP1AALDH1A1SMN1; SMN2ACE | |
| SCHEMBL7406144 | 0.95 | RAB9A (0.71) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL3172600 | 0.95 | RAB9A (0.71) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL3172593 | 0.95 | RAB9A (0.71) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| Hydrochloric Acid SCHEMBL27968384 | 0.93 | RAB9A (0.69) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| Hydrochloric Acid SCHEMBL28049456 | 0.93 | RAB9A (0.69) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL9176416 | 0.89 | RAB9A (0.60) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL25414655 | 0.87 | RAB9A (0.57) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL7871571 | 0.87 | RAB9A (0.57) | RAB9AALDH1A1SMN1; SMN2ACEREN | |
| SCHEMBL24661351 | 0.86 | FKBP1A (0.65) | RAB9AFKBP1AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer Pharma AG (DE) | 2012-07-25 | — | — | EP | disclosed |
| US-8101615-B2 | Chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, heart failure | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20080064704-A1 | 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-03-13 | — | — | US | disclosed |
| EP-1723121-A1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer HealthCare AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082864-A1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-09-09 | — | — | WO | disclosed |
| EP-0501997-B1 | N-ACYL-SUBSTITUTED AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | SMITHKLINE BEECHAM SPA (IT) | 1997-01-29 | — | — | EP | disclosed |
| US-5466858-A | Ruthenium catalyst, high selectivity with a carboxylic acid | UBE INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| US-5366981-A | N-acyl-substituted azacyclic compounds, processes for their preparaion, and their use as pharmaceuticals | DR LO ZAMBELETTI S.P.A. (IT) | 1994-11-22 | — | — | US | disclosed |
| US-5322848-A | Analgesics | DR. LO ZEMBELETTI S.P.A. (IT) | 1994-06-21 | — | — | US | disclosed |
| EP-0585296-A1 | 2-(PYRROLIDINYL-1-METHYL)-PIPERIDINE DERIVATIVES AND THEIR USE AS KAPPA-RECEPT OR AGONISTS | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1994-03-09 | — | — | EP | disclosed |
| WO-1992020657-A1 | 2-(PYRROLIDINYL-1-METHYL)-PIPERIDINE DERIVATIVES AND THEIR USE AS KAPPA-RECEPT OR AGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992017467-A1 | SUBSTITUTED AZACYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANALGESICS | DR LO. ZAMBELETTI S.P.A. (IT) | 1992-10-15 | — | — | WO | disclosed |
| EP-0502015-A1 | N-ACYL-SUBSTITUTED AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | Dr. Lo. Zambeletti S.p.A. (IT) | 1992-09-09 | — | — | EP | disclosed |
| EP-0501997-A1 | N-ACYL-SUBSTITUTED AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS. | ZAMBELETTI SPA L (IT) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991008206-A1 | N-ACYL-SUBSTITUTED AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | DR. LO. ZAMBELETTI S.P.A. (IT) | 1991-06-13 | — | — | WO | disclosed |
| WO-1991008205-A1 | N-ACYL-SUBSTITUTED AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | DR. LO. ZAMBELETTI S.P.A. (IT) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064704-A1 | 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors | SERPINB1, ELANE, MPO | RAB9A 1228/4885FKBP1A 1691/4885ALDH1A1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.